Ann Pediatr Endocrinol Metab.  2019 Jun;24(2):71-77. 10.6065/apem.2019.24.2.71.

Update on the current modalities used to screen high risk youth for prediabetes and/or type 2 diabetes mellitus

• Brar PC

• KMID: 2452082
• DOI: http://doi.org/10.6065/apem.2019.24.2.71

Abstract

The modalities currently employed to screen for type 2 diabetes mellitus (T2DM)/prediabetes are HbA1(c), fasting plasma glucose (FPG), and 2-hour plasma glucose (PG) during an oral glucose tolerance test (OGTT). The purpose of this review is to highlight the positive qualities and pitfalls of these diagnostic modalities and reflect on the most reasonable and effective approach to screen high risk youth. Given its inherent preanalytical advantages, glycated hemoglobin (HbA1(c)) continues to be the preferred diagnostic modality used by pediatricians to screen high risk youth. However, when the three aforementioned tests are performed in youths of different races/ethnicities, discrepant results for T2DM/prediabetes are observed. The prevalence rates for T2DM vary from 0.53% in Chinese youth (including youth of all body mass indexes) to 18.3% in high-risk, overweight, obese Korean youth. Moreover, the FPG is abnormal (>100 less than <126 mg/dL) in 15% of Korean youth versus 8.7% of Chinese youth. The prevalence rates for prediabetes are 1.49% in Chinese youth versus 21% in Emirati youth (HbA1(c), 5.7%-6.4%). The coefficient of agreement, k, between these screening tests for T2DM are fair, 0.45-0.5 across all youth. However, using HbA1(c) as a comparator, the agreement is weak with FPG (k=0.18 in German youth versus k=0.396 in Korean youth). The American Diabetes Association (ADA) Standards of Medical Care Guidelines define "high risk youth" who need to be tested for T2DM and/or prediabetes. OGTT and HbA1(c) do not always detect T2DM in similar individuals. HbA1(c) may not be an ideal test for screening Hispanic and African American youth. FPG and OGTT are suitable screening tests for youth of ethnic minorities and those with cystic fibrosis or hemoglobinopathies. Performing all three tests either together or sequentially may be the only way to encompass all youth who have aberrations in different aspects of glucose homeostasis.

Keyword

Type 2 diabetes mellitus; Prediabetic state; Glycated hemoglobin A; Fasting plasma glucose; Oral glucose tolerance test; Youth; Screening tests

MeSH Terms

Adolescent*
Asian Continental Ancestry Group
Blood Glucose
Cystic Fibrosis
Diabetes Mellitus, Type 2*
Fasting
Glucose
Glucose Tolerance Test
Hemoglobin A, Glycosylated
Hemoglobinopathies
Hispanic Americans
Homeostasis
Humans
Mass Screening
Overweight
Prediabetic State*
Prevalence
Glucose

Reference

References

1. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019; 42(Suppl 1):S13–28.

2. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014; 311:1778–86.

3. Dabelea D, Pettitt DJ, Jones KL, Arslanian SA. Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol Metab Clin North Am. 1999; 28:709–29.

4. Libman I, Arslanian SA. Type II diabetes mellitus: no longer just adults. Pediatr Ann. 1999; 28:589–93.

5. Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care. 2012; 35:2515–20.

6. Brar PC, Mengwall L, Franklin BH, Fierman AH. Screening obese children and adolescents for prediabetes and/or type 2 diabetes in pediatric practices: a validation study. Clin Pediatr (Phila). 2014; 53:771–6.

7. Weiss R. Impaired glucose tolerance and risk factors for progression to type 2 diabetes in youth. Pediatr Diabetes. 2007; 8 Suppl 9:70–5.

8. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care. 2018; 41:2648–68.

9. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20:1183–97.

10. Kleber M, Lass N, Papcke S, Wabitsch M, Reinehr T. One-year follow-up of untreated obese white children and adolescents with impaired glucose tolerance: high conversion rate to normal glucose tolerance. Diabet Med. 2010; 27:516–21.

11. Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005; 28:902–9.

12. Gallardo TV, Avila AA, Unuane MN, Codner E. Fasting glucose versus oral glucose tolerance test for detection of glucose intolerance in obese children. Rev Med Chil. 2006; 134:1146–52.

13. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32:1327–34.

14. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosisrelated diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010; 33:2697–708.

15. Brooks AP, Metcalfe J, Day JL, Edwards MS. Iron deficiency and glycosylated haemoglobin A. Lancet. 1980; 2:141.

16. Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012; 16:528–31.

17. Lacy ME, Wellenius GA, Sumner AE, Correa A, Carnethon MR, Liem RI, et al. Association of sickle cell trait with hemoglobin A1c in African Americans. JAMA. 2017; 317:507–15.

18. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008; 31:1991–6.

19. Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin A(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care. 2011; 34:1306–11.

20. Buse JB, Kaufman FR, Linder B, Hirst K, El Ghormli L, Willi S, et al. Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. Diabetes Care. 2013; 36:429–35.

21. Lee JM, Wu EL, Tarini B, Herman WH, Yoon E. Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr. 2011; 158:947–52. e1-3.

22. Yang C, Ding Z, Zhou H, Chen D, Huang Z, Yang C, et al. Prevalence of prediabetes by the fasting plasma glucose and HbA1c screening criteria among the children and adolescents of Shenzhen, China. J Diabetes. 2018; Jul. 4. [Epub]. https://doi.org/10.1111/1753-0407.12820.

23. Al Amiri E, Abdullatif M, Abdulle A, Al Bitar N, Afandi EZ, Parish M, et al. The prevalence, risk factors, and screening measure for prediabetes and diabetes among Emirati overweight/obese children and adolescents. BMC Public Health. 2015; 15:1298.

24. Nam HK, Cho WK, Kim JH, Rhie YJ, Chung S, Lee KH, et al. HbA1c cutoff for prediabetes and diabetes based on oral glucose tolerance test in obese children and adolescents. J Korean Med Sci. 2018; 33:e93.

25. Khokhar A, Naraparaju G, Friedman M, Perez-Colon S, Umpaichitra V, Chin VL. Comparison of A1C to oral glucose tolerance test for the diagnosis of prediabetes in overweight and obese youth. Clin Diabetes. 2017; 35:133–40.

26. Ehehalt S, Wiegand S, Körner A, Schweizer R, Liesenkötter KP, Partsch CJ, et al. Low association between fasting and OGTT stimulated glucose levels with HbA1c in overweight children and adolescents. Pediatr Diabetes. 2017; 18:734–41.

27. Yoon JS, So CH, Lee HS, Hwang JS. Glycated hemoglobin A1c as a screening test for detecting type 2 diabetes mellitus in obese children and adolescents. J Pediatr Endocrinol Metab. 2018; 31:503–6.

28. Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 2011; 34:960–7.

29. Chan CL, Pyle L, Newnes L, Nadeau KJ, Zeitler PS, Kelsey MM. Continuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth. J Clin Endocrinol Metab. 2015; 100:902–10.

30. Bergman M, Manco M, Sesti G, Dankner R, Pareek M, Jagannathan R, et al. Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour postload plasma glucose ≥ 155 mg/dl (8.6 mmol/L). Diabetes Res Clin Pract. 2018; 146:18–33.

31. Jagannathan R, Sevick MA, Fink D, Dankner R, Chetrit A, Roth J, et al. The 1-hour post-load glucose level is more effective than HbA1c for screening dysglycemia. Acta Diabetol. 2016; 53:543–50.

32. Abdul-Ghani MA, Abdul-Ghani T, Müller G, Bergmann A, Fischer S, Bornstein S, et al. Role of glycated hemoglobin in the prediction of future risk of T2DM. J Clin Endocrinol Metab. 2011; 96:2596–600.

33. Kasturi K, Onuzuruike AU, Kunnam S, Shomaker LB, Yanovski JA, Chung ST. Two- vs one-hour glucose tolerance testing: predicting prediabetes in adolescent girls with obesity. Pediatr Diabetes. 2019; 20:154–9.